Back to Search
Start Over
New antiplatelet agents in the treatment of acute coronary syndromes
- Source :
- Archives of Cardiovascular Diseases. 107(3):178-187
- Publication Year :
- 2014
- Publisher :
- Elsevier BV, 2014.
-
Abstract
- SummaryEffective antagonism of the P2Y12 platelet receptor is central to the treatment of acute coronary syndrome (ACS) patients, especially in the setting of percutaneous coronary intervention and stenting. According to consensus guidelines, early revascularization and intensive antiplatelet therapy are key to reducing the complications that arise from myocardial ischaemia and the recurrence of cardiovascular events. Until recently, clopidogrel was the key P2Y12 antagonist advocated, but due to several limitations as an antiplatelet agent, newer drugs with more predictable, rapid and potent effects have been developed. Prasugrel and ticagrelor are now the recommended first-line agents in patients presenting with non-ST-segment elevation ACS and ST-segment elevation ACS, due to large-scale randomized trials that demonstrated net clinical benefit of these agents over clopidogrel, as stated in the European guidelines. Although no study has directly compared the two agents, analysis of the data to date suggests that certain patient types, such as diabetics, those with ST-segment elevation myocardial infarction or renal failure and the elderly may have a better outcome with one agent over the other. Further studies are needed to confirm these differences and answer pending questions regarding the use of these drugs to optimize efficacy while minimizing adverse events, such as bleeding. The aim of this review is to provide an overview of the current P2Y12 receptor antagonists in the treatment of ACS, with a focus on issues of appropriate agent selection, timing of treatment, bleeding risk and the future role of personalized treatment using platelet function and genetic testing.
- Subjects :
- Ticagrelor
Prasugrel
Adenosine
medicine.medical_treatment
Piperazines
P2Y12
Multicenter Studies as Topic
Myocardial infarction
Renal Insufficiency
Coronary Artery Bypass
Precision Medicine
Randomized Controlled Trials as Topic
Clinical Trials as Topic
General Medicine
Clopidogrel
Combined Modality Therapy
Receptors, Purinergic P2Y12
Treatment Outcome
Practice Guidelines as Topic
Molécules antiplaquettaires
Cardiology
Cardiology and Cardiovascular Medicine
TIMI
medicine.drug
Acute coronary syndrome
medicine.medical_specialty
Ticlopidine
P2Y12 receptor antagonist
Hemorrhage
Thiophenes
Diabetes Complications
Internal medicine
medicine
Humans
Acute Coronary Syndrome
Intensive care medicine
Réactivité plaquettaire
business.industry
Coronary Thrombosis
Antagoniste du récepteur P2Y12
Percutaneous coronary intervention
medicine.disease
Antiplatelet drugs
Adenosine Monophosphate
Purinergic P2Y Receptor Antagonists
Platelet reactivity
business
Prasugrel Hydrochloride
Platelet Aggregation Inhibitors
Subjects
Details
- ISSN :
- 18752136
- Volume :
- 107
- Issue :
- 3
- Database :
- OpenAIRE
- Journal :
- Archives of Cardiovascular Diseases
- Accession number :
- edsair.doi.dedup.....8506518fd4e0b195f8e428e4571cb72d
- Full Text :
- https://doi.org/10.1016/j.acvd.2014.01.009